Literature DB >> 6756175

Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669).

T M Cosgriff, E F Boudreau, C L Pamplin, E B Doberstyn, R E Desjardins, C J Canfield.   

Abstract

Halofantrine (WR 171,669) was administered to 27 nonimmune subjects infected with the multi-drug resistant Vietnam Smith strain of Plasmodium falciparum. It was also administered to three other subjects, one infected with the Cambodian Buchanan strain of P. falciparum, and two with blood-induced infection with the Chesson strain of P. vivax. It cured infections with all three parasites. Against the highly chloroquine-resistant Smith strain, it was curative in single day treatment regimens. The drug was well tolerated and produced rapid clearance of parasitemia in every case.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6756175     DOI: 10.4269/ajtmh.1982.31.1075

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

Review 1.  A lesson learnt: the rise and fall of Lariam and Halfan.

Authors:  Ashley M Croft
Journal:  J R Soc Med       Date:  2007-04       Impact factor: 5.344

Review 2.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Development of halofantrine resistance and determination of cross-resistance patterns in Plasmodium falciparum.

Authors:  M Nateghpour; S A Ward; R E Howells
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

4.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

5.  Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.

Authors:  D R Abernethy; D L Wesche; J T Barbey; C Ohrt; S Mohanty; J C Pezzullo; B G Schuster
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 6.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

7.  A clinical trial with halofantrine on patients with falciparum malaria in Colombia.

Authors:  M Restrepo; D Botero; R E Marquez; E F Boudreau; V Navaratnam
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 8.  Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; K L Goa
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of halofantrine.

Authors:  J Karbwang; K Na Bangchang
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

10.  Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine.

Authors:  J R Veenendaal; A D Parkinson; N Kere; K H Rieckmann; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.